Efficacy of Escitalopram, Venlafaxine and Buspirone in Irritable Bowel Syndrome
- Conditions
- Irritable bowel syndrome.Irritable bowel syndrome
- Registration Number
- IRCT20150630022991N10
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
The Presence of ROME-III Diagnostic Criteria for Diagnosis of Irritable Bowel Syndrome
To Provide the Informed Consent Form of the Patient for Participation in the Study
Age under 18 years
Allergy to Escitalopram, Venlafaxine or Buspirone
The presence of warning signs such as chronic fever, weight loss, gastrointestinal bleeding
Pregnancy and breast feeding
Use of any drug that can affect the bowel function (such as laxatives, anti-diarrhea, antibiotics and probiotics) within one month before entering the study
Known cases of lactose intolerance
Severe physical illnesses, mental retardation, dementia, psychosis, and the existence of serious suicidal ideation and substance dependence that affects patients' compliance with the study protocol
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Irritable bowel syndrome symptoms. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to ROME-III diagnostic criteria.;Patient´s quality of life. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to the quality of life questionnaire IBS_QOL.
- Secondary Outcome Measures
Name Time Method The drug side effects. Timepoint: At the fourth and eighth weeks of the intervention. Method of measurement: Visit of the patient.